Sirolimus
Sign in to save this workspacePrimary targets: FKBP12, MTOR_FRAP1 · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.708
CATDS
0.023
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Sirolimus. Strongest target: ERN1_IRE1 at 31.9% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ERN1_IRE1 | 31.9% | 68.1% |
| 2 | CAMKK2 | 30.4% | 69.6% |
| 3 | PKMYT1 | 29.5% | 70.5% |
| 4 | PDK2_PDHK2 | 26.8% | 73.2% |
| 5 | WNK1 | 24.1% | 75.9% |
| 6 | STK21_CIT | 23.1% | 76.9% |
| 7 | MUSK | 22.9% | 77.1% |
| 8 | GSK3A | 22.3% | 77.7% |
| 9 | STK33 | 20.6% | 79.4% |
| 10 | PHKG1 | 19.8% | 80.2% |
| 11 | EGFR | 18.0% | 82.0% |
| 12 | CTK_MATK | 17.9% | 82.1% |
| 13 | MLK3_MAP3K11 | 17.8% | 82.2% |
| 14 | TTBK2 | 16.0% | 84.0% |
| 15 | SLK_STK2 | 15.6% | 84.4% |
| 16 | STK39_STLK3 | 14.9% | 85.1% |
| 17 | SSTK_TSSK6 | 14.7% | 85.3% |
| 18 | TTBK1 | 14.2% | 85.8% |
| 19 | BMPR2 | 13.8% | 86.2% |
| 20 | KSR2 | 13.2% | 86.8% |
Selectivity landscape
Where Sirolimus sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Sirolimus.
Atlas insights for Sirolimus
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 326.79 | |
| ALLOGRAFT_REJECTION | 739.91 | |
| ANDROGEN_RESPONSE | 438.46 | |
| ANGIOGENESIS | 128.57 | |
| APICAL_JUNCTION | 852.47 | |
| APICAL_SURFACE | 100.88 | |
| APOPTOSIS | 1143.30 | |
| BILE_ACID_METABOLISM | 161.84 | |
| CHOLESTEROL_HOMEOSTASIS | 238.90 | |
| COAGULATION | 113.64 | |
| COMPLEMENT | 535.79 | |
| DNA_REPAIR | 359.09 | |
| E2F_TARGETS | 908.76 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 293.95 | |
| ESTROGEN_RESPONSE_EARLY | 504.57 | |
| ESTROGEN_RESPONSE_LATE | 451.86 | |
| FATTY_ACID_METABOLISM | 89.00 | |
| G2M_CHECKPOINT | 819.45 | |
| GLYCOLYSIS | 398.62 | |
| HEDGEHOG_SIGNALING | 144.47 | |
| HEME_METABOLISM | 294.95 | |
| HYPOXIA | 734.71 | |
| IL2_STAT5_SIGNALING | 437.26 | |
| IL6_JAK_STAT3_SIGNALING | 554.24 | |
| INFLAMMATORY_RESPONSE | 549.56 | |
| INTERFERON_ALPHA_RESPONSE | 108.00 | |
| INTERFERON_GAMMA_RESPONSE | 664.33 | |
| KRAS_SIGNALING_DN | 178.63 | |
| KRAS_SIGNALING_UP | 368.24 | |
| MITOTIC_SPINDLE | 858.35 | |
| MTORC1_SIGNALING | 552.40 | |
| MYC_TARGETS_V1 | 526.92 | |
| MYC_TARGETS_V2 | 155.27 | |
| MYOGENESIS | 519.46 | |
| NOTCH_SIGNALING | 115.08 | |
| OXIDATIVE_PHOSPHORYLATION | 110.32 | |
| P53_PATHWAY | 670.69 | |
| PANCREAS_BETA_CELLS | 103.74 | |
| PEROXISOME | 153.44 | |
| PI3K_AKT_MTOR_SIGNALING | 1150.65 | |
| PROTEIN_SECRETION | 264.37 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 106.55 | |
| SPERMATOGENESIS | 263.99 | |
| TGF_BETA_SIGNALING | 386.76 | |
| TNFA_SIGNALING_VIA_NFKB | 778.05 | |
| UNFOLDED_PROTEIN_RESPONSE | 191.34 | |
| UV_RESPONSE_DN | 512.55 | |
| UV_RESPONSE_UP | 505.12 | |
| WNT_BETA_CATENIN_SIGNALING | 448.82 | |
| XENOBIOTIC_METABOLISM | 247.29 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.880 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.854 |
| SRR12202498 | — | 0.843 |
| SRR1443713 | GTEX | 0.841 |
| SRR23303752 | — | 0.840 |
Annotations
Sign in to read and post annotations.
Loading…